Genovac was initially launched in 1999 by three University of Freiburg professors who built on the institution’s contributions to pioneering antibody discovery research and development. Focused on delivering the most advanced genetic immunization and hybridoma technologies, the founders created the gold standard of the time for the generation of antibodies against challenging targets.
With the management led buyout of the Aldevron’s antibody discovery business unit, we’re proud to relaunch Genovac and to redefine the gold standard for the delivery of antibodies against challenging targets through continuous improvement of our immunization technologies and novel use of Berkeley Light’s Beacon instrument.